Efficacy of amikacin, ofloxacin, pefloxacin, ciprofloxacin, enoxacin and fleroxacin in experimental left-sided Pseudomonas aeruginosa endocarditis

Chemotherapy

Volumn 46, Issue 2, 2000, Pages 116-121

  Papadakis, J A ^a   Samonis, G ^a   Maraki, S ^a   Boutsikakis, J ^b   Petrocheilou, V ^c   Saroglou, G ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

Author keywords

Amikacin; Ciprofloxacin; Enoxacin; Experimental endocarditis; Fleroxacin; Ofloxacin; Pefloxacin; Pseudomonas aeruginosa; Rabbits

Indexed keywords

AMIKACIN; CIPROFLOXACIN; ENOXACIN; FLEROXACIN; OFLOXACIN; PEFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENDOCARDITIS; FEMALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT; SURVIVAL;

EID: 0033961389     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007265     Document Type: Article

References (33)

1. Revs MP, Lerner AM: Current problems in the treatment of infective endocarditis due to P. aeruginosa. Rev Infect Dis 1983;5:314-320.
2. Archer G, Fekety FR, Supena R: P. aeruginosa endocarditis in drug addicts. Am Heart J 1974;88:570-578.
3. Dismukes WE, Karhmer AW, Buckley MJ, Austen WG, Swartz MN: Prosthetic valve endocarditis: Analysis of 38 cases. Circulation 1973; 48:365-377.
4. Preheim LC, Penn RG, Sanders CC, Goering RV, Giger DK: Emergence of resistance to β-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 1982;22:1037-1041.
5. Sanders CC, Sanders WE Jr: Emergence of resistance during therapy with the newer β-lactam antibiotics: Role of inducible β-lactamases and implications for the future. Rev Infect Dis 1983;5:639-648.
6. Chalkley LJ. Koornhof HJ: Antimicrobial activity of ciprofloxacin against Pseudumonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: Antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother 1985;28:331-342.
7. Eron LJ, Harvey L, Hixon DL, Poetz DM: Ciprofloxacin therapy of infection caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 1985;27:308-310.
8. Zak O, O'Reilly T: Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother 1991;35:1527-1531.
9. Durack DT, Beeson PB: Experimental bacterial endocarditis. II. Survival of bacteria in endocardial vegetations. Br J Exp Pathol 1972;53:50-53.
10. Pefanis A, Giamarellou H, Karayiannakos P, Donta I: Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother 1993;37: 308-313.
11. Young LS, Armstrong D: Human immunity to Pseudomonas aeruginosa. I. In vitro interaction of bacteria, polymorphonuclear leucocytes and serum factors. J Infect Dis 1972; 126:257-276.
12. National Committee for Clinical Laboratory Standards: Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. Villanova, National Committee for Clinical Laboratory Standards, 1993.
13. Drugeon HB, Le Gallou F. Caillon J: Methodes d'étude de l'activité bactéricide; in Courvalin P, Drugeon H, Flandrois JP, Goldstein F (eds): Bactéricidie. Paris. Maloine, 1990, pp 113-126.
14. Garrison PK, Freedman LR: Experimental endocarditis. I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J Biol Med 1970;42: 394-410.
15. Perlman BB, Freedman LR: Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a catheter in the left side of the heart. Yale J Biol Med 1971;44:206-213.
16. Norris S, Nightingale CH, Mandell GL: Tables of antimicrobial agent pharmacology; in Mandell GL, Douglas RG Jr. Bennett JE (eds): Principles and Practice of Infectious Diseases, ed 3. New York, Churchill-Livingstone, 1990, pp 440-455.
17. Bayer AS, Blomquist IK, Kim KS: Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother 1986;17:641-649.
18. Archer G, Fekety FR: Experimental endocarditis due to Pseudomonas aeruginosa. I, Description of a model. J Infect Dis 1976;134:1-7.
19. Bayer AS, Norman D, Kim KS: Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chcmother 1985;28:781-785.
20. Strunk RW, Gratz JC, Maserati R, Scheid WM: Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomanas aeruginosa endocarditis. Antimicrob Agents Chemother 1985;28:428-432.
21. Godfrey K: Comparing the meansof several groups. N Engl J Med 1985; 313:1450-1456.
22. Carbon C: Experimental endocarditis: A review of its relevance to human endocarditis. J Antimicrob Chemother 1993:31(suppl D):71-85.
23. Xiong YQ, Caillon J, Zhou XY, Potel G, Bugnon D, Le Conte P, Le Gallou F, Le Floch R, Baron D, Drugcon H: Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginusa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both. J Antimicrob Chemother 1995;35: 697-706.
24. Jackson GG, Riff LJ: Pseudomonas bacteremia: Pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis 1971; 124(suppl):185-191.
25. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA: Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988;158: 7-12.
26. De Broe ME, Giuliano RA, Verpooten GA: Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986;80(suppl 6B):115-118.
27. Laurent G, Kishora BK, Tulkens PM: Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990;40: 2383-2392.
28. Stratton C: Fluoroquinolone antibiotics: Properties of the class and individual agents. Clin Ther 1992;14: 348-375.
29. Auckenthaler RN, Michea-Hamzehpour M, Perchere JC: In vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother 1986;17:29-39.
30. Bayer AS, Lindsay P, Yih J, Hirano L, Lee D, Blomquist IK: Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply β;-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for β-lactamase production. Antimicrob Agents Chemother 1986;30:528-531.
31. Xiong YQ, Potel G, Caillon J, Stephant G, Jehl F, Bugnon D, Le Conte P, Baron D, Drugeon H: Comparative efficacies of ciprofloxacin and pefloxacin alone with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:496-499.
32. Bayer AS, Hirano L, Yih J: Development of β-lactam-resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother 1988; 32:231-235.
33. Neu H: Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis 1989:11(suppl 5):1025-1035.